Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment

Facing the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to find protective or curable drugs to prevent or to stop the course of the coronavirus SARS-CoV-2 infection. Recent evidence accumulates that adamantanes, widely used in different neurological diseases, cou...

Descripción completa

Detalles Bibliográficos
Autores principales: Rejdak, Konrad, Grieb, Paweł
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190496/
https://www.ncbi.nlm.nih.gov/pubmed/32388458
http://dx.doi.org/10.1016/j.msard.2020.102163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190496/
https://www.ncbi.nlm.nih.gov/pubmed/32388458
http://dx.doi.org/10.1016/j.msard.2020.102163

Ejemplares similares